Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Dapagliflozin
93%
Glucose
79%
Therapeutic Procedure
63%
Plasma
51%
Gluconeogenesis
51%
Insulin
44%
Placebo
42%
Patient
40%
Insulin Sensitivity
36%
Pioglitazone
33%
Combination Therapy
31%
Glucosuria
30%
Patient with Type 2 Diabetes
29%
Inpatient
27%
Insulin Resistance
26%
Cell Function
25%
Hyperglycemia
22%
Glucagon-Like Peptide-1 Agonist
22%
Glucagon
19%
Oral Glucose Tolerance Test
19%
Cardiovascular System
18%
Glucose Tolerance
17%
Insulin Release
16%
Kidney
15%
Metabolic Syndrome
15%
Exenatide
15%
Diagnosis
15%
Cotransporter
14%
Antidiabetic Agent
14%
Glucose Uptake
13%
Cells
13%
Diabetes
13%
Type 2 Diabetes
13%
Adipose Tissue
12%
Creatine Phosphate
12%
Empagliflozin
12%
Heart
12%
Heritability
12%
Ketone
12%
Adenosine Triphosphate
11%
Acipimox
10%
Hemoglobin A1c
10%
Deterioration
10%
Chemotherapeutic Agent
9%
Drug
9%
Urinary System
9%
Diseases
9%
Thiazolidinedione
8%
Drug Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
58%
Semaglutide
25%
Pioglitazone
25%
Dapagliflozin
23%
Glucose
15%
Hemoglobin A1c
10%
Antidiabetic Agent
10%
Glitazone Derivative
10%
Diseases
9%
Insulin
8%
Empagliflozin
8%
Placebo
8%
Linagliptin
8%
Drug
8%
Adverse Event
7%
Insulin Resistance
7%
Glucagon
7%
Saxagliptin
6%
Hyperglycemia
6%
Hypoglycemia
6%
Combination Therapy
6%
Kidney Disease
6%
Diabetes Mellitus
5%
Cotransporter
5%
Glucagon Like Peptide 1 Receptor Agonist
5%
Dipeptidyl Peptidase IV Inhibitor
5%
Monotherapy
5%
Nursing and Health Professions
Glucose
22%
Glucose Blood Level
17%
Non Insulin Dependent Diabetes Mellitus
17%
Glucagon Like Peptide 1 Receptor Agonist
16%
World Health Organization
12%
Metabolic Syndrome X
12%
Pioglitazone
12%
Empagliflozin
12%
Dapagliflozin
12%
Diagnosis
12%
Insulin
12%
Insulin Resistance
11%
Clamp
10%
Acipimox
10%
Diabetes Mellitus
10%
Family
10%
Drug
9%
Hyperglycemia
9%
Glucose Level
9%
Antidiabetic Agent
8%
Obesity
7%
Procedures
6%
Inpatient
6%
Glucose Infusion
5%
Adverse Event
5%
Cardiovascular Risk
5%
Fatty Acid Blood Level
5%
Adult
5%
Prevalence
5%
Triacylglycerol
5%
